Most Patients With HIV Opted for Injectable ART, PrEP in Phase 3 Trial
New data demonstrated that long-acting cabotegravir was
preferable to daily dolutegravir/lamivudine in treatment-naive people living
with HIV. |
Updates & Legacy — Stigmabase is a Canadian Non-Governmental & Nonprofit Initiative. Our mission is to inform about stigma around the world and make the data collected accessible for researchers. Stigmabase is very attentive to misinformation and lists only reliable sources. — The marginalization of individuals or categories of individuals is a too common phenomenon. Millions of people are facing this problem around the world and many complex factors are involved.